Published in BMC Cancer on February 08, 2016
Metabolic profiling of presymptomatic Huntington's disease sheep reveals novel biomarkers. Sci Rep (2017) 0.75
The clinical picture of cachexia: a mosaic of different parameters (experience of 503 patients). BMC Cancer (2017) 0.75
Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for Inflammation. Oxid Med Cell Longev (2017) 0.75
Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol (2017) 0.75
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 12.98
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell (2004) 11.33
FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab (2007) 8.90
FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab (2007) 8.05
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell (2004) 6.25
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science (2000) 5.20
Induction of cachexia in mice by systemically administered myostatin. Science (2002) 4.39
Mechanisms of cancer cachexia. Physiol Rev (2009) 4.03
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab (2012) 3.29
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol (2009) 3.18
Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem (2002) 3.07
During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol (2009) 3.03
Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol (2009) 2.75
Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res (2009) 2.57
Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol (2010) 2.47
Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol (2012) 2.45
The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem (2005) 2.44
Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail (2010) 2.40
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest (2005) 2.24
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation (2010) 2.23
Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr (2012) 2.14
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest (2007) 1.98
Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy (2008) 1.95
Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) (2008) 1.86
Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2012) 1.83
Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care (2010) 1.79
The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol (2005) 1.79
Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr (2010) 1.76
Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer (2008) 1.67
STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One (2011) 1.61
NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest (2013) 1.60
Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res (2007) 1.59
p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol (2009) 1.57
The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer (1996) 1.57
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab (2012) 1.56
Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol (2002) 1.53
Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine (1999) 1.50
Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer (1997) 1.48
Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J (2010) 1.46
Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract (2011) 1.45
Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun (2009) 1.45
Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol (2005) 1.41
Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle (2012) 1.40
Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J (2011) 1.39
Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS One (2009) 1.37
The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle (2011) 1.36
Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol (2009) 1.35
Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer (2005) 1.31
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg (2003) 1.28
Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse. Pflugers Arch (2008) 1.27
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther (2011) 1.26
The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery (1999) 1.26
Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest (2006) 1.22
Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res (2001) 1.21
The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One (2011) 1.20
Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer (2003) 1.20
Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem (2007) 1.19
Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer (2003) 1.18
Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res (2005) 1.18
Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer (2001) 1.18
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med (2010) 1.18
Lysosomal proteolysis in skeletal muscle. Int J Biochem Cell Biol (2005) 1.18
IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol (2010) 1.17
Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev (2010) 1.16
The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol (Oxf) (2012) 1.15
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 1.14
Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med (2007) 1.13
Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab (2012) 1.12
TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care (2012) 1.12
IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol (2006) 1.11
Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology (2007) 1.11
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol (2008) 1.11
Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg (2000) 1.10
The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol Cell Biol (2012) 1.10
Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res (1998) 1.10
Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J (2007) 1.09
Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer (1996) 1.09
Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol (2013) 1.09
Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol (2011) 1.08
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol (2004) 1.07
Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract (2004) 1.07
TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A. Skelet Muscle (2012) 1.07
Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle (2012) 1.06
Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci (2011) 1.06
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer (2010) 1.05
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev (2004) 1.05
Myocardial dysfunction in an animal model of cancer cachexia. Life Sci (2010) 1.04
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer (2007) 1.03
Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition (2005) 1.03
Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer (2001) 1.03
The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail (2001) 1.03
Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal (2007) 1.03
Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther (2007) 1.02